A5044687687- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Advanced Breast Cancer Therapies
- Biosimilars and Bioanalytical Methods
- CNS Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Integrated Circuits and Semiconductor Failure Analysis
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Viral Infectious Diseases and Gene Expression in Insects
- Glioma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Biomedical Ethics and Regulation
- MicroRNA in disease regulation
- Cancer Immunotherapy and Biomarkers
- Acute Myeloid Leukemia Research
- Virus-based gene therapy research
- Advancements in Semiconductor Devices and Circuit Design
- Immunotherapy and Immune Responses
- Phagocytosis and Immune Regulation
- Glycosylation and Glycoproteins Research
- Multiple and Secondary Primary Cancers
University of Cologne
2014-2025
Heinrich Heine University Düsseldorf
2019-2025
Düsseldorf University Hospital
2019-2025
University Hospital Cologne
2016-2025
Integrated Oncology (United States)
2022
Centrum für Integrierte Onkologie
2021
Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases
2009-2019
German Inflammatory Bowel Diseases Study Group
2019
Abstract Deciphering the evolution of cancer cells under therapeutic pressure is a crucial step to understand mechanisms that lead treatment resistance. To this end, we analyzed whole-exome sequencing data eight chronic lymphocytic leukemia (CLL) patients developed resistance upon BCL2-inhibition by venetoclax. Here, report recurrent mutations in BTG1 (2 patients) and homozygous deletions affecting CDKN2A/B (3 during treatment, as well mutation BRAF high-level focal amplification CD274 (...
The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, could be a promising treatment target. We report dose escalation results from the ongoing phase 1/2 BNT211-01 trial evaluating safety feasibility of chimeric receptor (CAR) T cells targeting CLDN6 with or without CAR-T cell-amplifying RNA vaccine (CARVac) at two levels (DLs) relapsed/refractory CLDN6-positive tumors. primary endpoints were tolerability, maximum tolerated recommended 2 (RP2D)....
In the primary analysis report of GAIA/CLL13 trial, we found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib improved undetectable measurable residual disease (MRD) rates progression-free survival compared with chemoimmunotherapy in patients previously untreated chronic lymphocytic leukaemia. However, to our knowledge, no data on direct comparisons different venetoclax-based combinations are available.
Supplemental Digital Content is available in the text
We report the first culture-proven case of invasive aspergillosis (IA) caused by azole-resistant Aspergillus fumigatus in a patient with acute myeloid leukaemia Germany. IA presented as breakthrough infection under posaconazole prophylaxis. Analysis resistance mechanism revealed TR/L98H mutation cyp51A gene, which indicates an environmental origin strain. This underscores need for monitoring azole spp. and routine susceptibility testing moulds.
Ziel/Aim: Chimeric antigen receptor (CAR) T-cell therapy has proven highly effective in relapsed and refractory large B-cell lymphomas. Yet, it remains an open question how to identify potential non-responders ahead of treatment further improve their outcome. Several international research groups are currently working on the integration metabolic tumor volume (MTV), measured by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (PET), into newly developed models. Therefore, we...
We report on a case of severe prolonged pancytopenia after CD19 CAR T-cell (CART) therapy for aggressive lymphoma that successfully resolved autologous peripheral blood stem cell transplantation (ASCT). A 51-year-old female suffered from germinal center-type double-hit diffuse large B-cell (DLBCL). Besides hypertension, deep vein thrombosis, and hypothyroidism, she had no relevant preexisting conditions. Beginning in December 2018, received 6 cycles rituximab, cyclophosphamide, doxorubicin,...
The introduction of chimeric antigen receptor (CAR) T-cell therapy has led to a fundamental shift in the management relapsed and refractory large B-cell lymphoma. However, our understanding risk factors associated with non-response is still insufficient search for predictive biomarkers continues. Some parameters measurable on 18 F-fluorodeoxyglucose positron emission tomography (PET) may be additional value this context. A total 47 individuals from three German university centers who...
Abstract Purpose The emergence of chimeric antigen receptor (CAR) T-cell therapy fundamentally changed the management individuals with relapsed and refractory large B-cell lymphoma (LBCL). However, real-world data have shown divergent outcomes for approved products. present study therefore set out to evaluate potential risk factors in a larger cohort. Methods Our analysis included 88 patients, treated four German university hospitals one Italian center, who had undergone 2-[ 18...
7002 Background: In the era of more effective treatments for CLL, established clinical staging systems [Rai/Binet] do not accurately discriminate between prognostic groups. There are several new markers, but no system integrates major clinical, biological and genetic variables into one widely accepted score. Therefore we performed a comprehensive analysis 26 factors to develop an internationally applicable index CLL patients (pts) [CLL-IPI]. Methods: Our full set (FAS) was collected from 8...
Targeting the B-cell receptor (BCR) pathway in chronic lymphocytic leukemia (CLL) with novel agents that inhibit Bruton’s tyrosine kinase (BTK), such as ibrutinib and acalabrutinib, those inhibiting delta isoform of phosphatidylinositol 3-kinase, idelalisib, improved outcomes substantially.1–3 Despite high overall response rates (ORRs) these agents, complete remissions (CRs) are rare, treatment is typically continued indefinitely until disease progression. Another potential target BCR spleen...
2518 Background: We are developing a chimeric antigen receptor (CAR)-T cell therapy targeting claudin 6 (CLDN6), an oncofetal that is undetectable in healthy somatic tissue and highly expressed various solid cancers. Autologous CLDN6 CAR-T cells being tested alone combination with CLDN6-encoding Amplifying RNA Vaccine (CARVac), nanoparticulate vaccine designed to stimulate expand cells. Methods: The ongoing first-in-human trial BNT211-01 evaluates the safety feasibility of transfer ± CARVac...
The chemoimmunotherapy FCR (fludarabine and cyclophosphamide with rituximab) is the standard first-line treatment for physically fit chronic lymphocytic leukemia (CLL) patients. To assess risks benefits, we investigated health-related quality of life (HRQOL). 817 untreated CLL patients received either FC or within GCLLSG CLL8 trial. European Organization Research Treatment Cancer Quality Questionnaire C30 was sent to all at baseline, after 3, 6, 12 months then yearly as follow-up. A total...
Abstract Chronic lymphocytic leukemia (CLL)‐related symptoms impair the well‐being of patients, making improvement health‐related quality life (QoL) a goal treatment. The CLL14 trial demonstrated higher efficacy fixed‐duration venetoclax‐obinutuzumab (Ven‐Obi) compared to chlorambucil‐obinutuzumab (Clb‐Obi) in patients with previously untreated CLL. To assess patients' QoL, following patient‐reported outcomes (PRO) measures were assessed: M.D. Anderson Symptom Inventory (MDASI) core...